Topics Related to Immunization - HCPs

We are pleased to share the North Carolina Immunization Program (NCIP) has launched a North Carolina RSV Immunization Honor Roll webpage. 

RSV is the leading cause of infant hospitalizations in the United States. The RSV Honor Roll highlights birthing hospitals across the state that ensure every newborn has access to RSV immunization prior to hospital discharge.

Dear Providers, 

This message is to remind you that COVID-19 vaccine ordering is open. We ask all providers to place orders and complete the accompanying survey to support vaccine access in your community.

Effective Tuesday, October 21, 2025, the NCIP is transitioning RSV vaccine ordering from the Smartsheet Request Form to the North Carolina Immunization Registry (NCIR).

Note: All orders previously placed through Smartsheet have been processed.

Please monitor your inventory and maintain sufficient stock to meet the needs of Vaccines for Children (VFC)-eligible patients throughout the 2025–2026 respiratory season.

Dear Local Health Departments,

On Oct. 6, 2025, the Acting CDC Director approved the Advisory Committee on Immunization Practices (ACIP) COVID-19 vaccine recommendations. The CDC has updated its adult and child immunization schedules to apply individual-based decision-making to COVID-19 vaccination for 6 months and older, after consultation with a health care provider.   

North Carolina Vaccines for Children (VFC) providers can now order the pentavalent meningococcal (A,B,C,W, and Y) vaccine, PENMENVY™ (NDC 58160-757-15) via NCIR for administration to their VFC-eligible adolescents (ages 10 through 18 years).

This email is to inform you that the North Carolina Immunization Program (NCIP) has opened applications for birthing hospitals interested in participating in the replacement model for birth dose Hepatitis B and RSV.

The purpose of this email is to inform VFC-enrolled providers that the RSV monoclonal antibody product clesrovimab (trade name ENFLONSIA™ manufactured by Merck) is now available for ordering. VFC doses will begin shipping after Oct. 2, 2025.

Clesrovimab is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants under 8 months of age who are born during or entering their first RSV season and who are not protected through maternal RSV vaccination.